Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authorsvan der Groep, P.
van der Zanden, R.
Menko, F. H.
Gille, J. J. P.
van Kalken, C.
van der Wall, E.
Verheijen, R. H. M.
van Diest, P. J.
MetadataShow full item record
AbstractBACKGROUND: About 5% of all breast cancer cases are attributable to germline mutations in BRCA1 or BRCA2 genes. BRCA mutations in suspected carriers, however, may be missed, which hampers genetic counselling. MATERIALS AND METHODS: Different clinicopathological features were compared between 22 breast cancers from carriers of proved BRCA1 mutations and 604 cancers from sporadic controls. In addition, 5 BRCA2-related breast cancers and 66 breast cancers of untested patients at intermediate risk and 19 breast cancers of untested patients at high risk of hereditary disease on the basis of family history were evaluated. RESULTS: A "probably sporadic" class (age >or=54 years and epidermal growth factor receptor (EGFR) negative; 68% of cases) with a 0% chance of BRCA1-related breast cancer containing 79% of the sporadic cases was yielded by using a decision tree with age, Ki67 and EGFR. A 75% chance of BRCA1-related breast cancer was shown by the "probably BRCA1-related" class (age <54 years and Ki67 >or=25%; 8% of cases) with 82% of the BRCA1-related cases but only 1.4% of the sporadic cases. Most cases at intermediate or high risk of hereditary disease on the basis of family history could be classified with high probability as either probably BRCA1 related or probably sporadic. CONCLUSION: Breast carcinomas can be classified with a high level of certainty as sporadic or related to BRCA1 germline mutations by using a decision tree with age, Ki67 and EGFR. This can be clinically useful in mutation analysis in families with a borderline risk of hereditary disease.
CitationJ. Clin. Pathol. 2006, 59 (6):611-617
JournalJournal of clinical pathology
DescriptionKEYWORDS CLASSIFICATION: analysis;Adult;Age Factors;Aged;Aged,80 and over;biomarkers of exposure & effect: field studies;Breast;Breast Neoplasms;diagnosis;Decision Trees;Diagnosis,Differential;Epidermal Growth Factor;Female;genetics;Genes,Brca1;Genes,Brca2;Genetic Predisposition to Disease;Germ-Line Mutation;history;Heterozygote;Humans;Immunoenzyme Techniques;Ki-67 Antigen;metabolism;Middle Aged;Neoplasm Proteins;Neoplastic Syndromes,Hereditary;Netherlands;pathology;Proteins;Receptor,Epidermal Growth Factor;Tumor Markers,Biological;field studies.
- Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
- Authors: Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT
- Issue date: 2005 May
- Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
- Authors: Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC
- Issue date: 2004 Nov
- Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
- Authors: Kirova YM, Stoppa-Lyonnet D, Savignoni A, Sigal-Zafrani B, Fabre N, Fourquet A, Institut Curie Breast Cancer Study Group.
- Issue date: 2005 Oct
- Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
- Authors: van der Groep P, van Diest PJ, Menko FH, Bart J, de Vries EG, van der Wall E
- Issue date: 2009 Oct